
SEOUL -- Samsung Biologics has become South Korea's third-most-valuable company, besting the much larger Hyundai Motor thanks to its status as a rare winner in the coronavirus economy.
Drugmaker's market cap surges to $31bn on lucrative virus treatment deal
SEOUL -- Samsung Biologics has become South Korea's third-most-valuable company, besting the much larger Hyundai Motor thanks to its status as a rare winner in the coronavirus economy.
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.